German guideline for diagnosis and management of idiopathic pulmonary fibrosis;S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose

Pneumologie

Volumn 67, Issue 2, 2013, Pages 81-111

  Behr, J ^a   Gunther A ^b,c   Ammenwerth, W ^d   Bittmann, I ^e   Bonnet, R ^f   Buhl, R ^g   Eickelberg, O ^h   Ewert, R ⁱ   Glaser S ⁱ   Gottlieb, J ^j   Grohe C ^k   Kreuter, M ^l   Kroegel, C ^m   Markart, P ^b   Neurohr, C ^a   Pfeifer, M ⁿ   Prasse, A ^o   Schonfeld N ^d   Schreiber, J ^p   Sitter, H ^c,q   Theegarten, D ^r   Theile, A ^s   Wilke, A ^k   Wirtz, H ^t   Witt, C ^u   Worth, H ^v   Zabel, P ^w   Muller Quernheim J ^o   Costabel, U ^r   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c Lungenfachklinik Waldhof Elgershausen ^*  (Germany)

^d HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^e Pathologisches Institut   (Germany)

^f ZENTRALKLINIK BAD BERKA   (Germany)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k Klinik fur Pneumologie   (Germany)

^l UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^m FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

ⁿ Klinik Donaustauf   (Germany)

^o UNIVERSITY OF FREIBURG   (Germany)

^p UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^q PHILIPPS UNIVERSITY MARBURG   (Germany)

^r UNIVERSITY HOSPITAL ESSEN   (Germany)

^s INSTITUT FÜR PATHOLOGIE   (Germany)

^t UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^u CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^v KLINIKUM FÜRTH   (Germany)

^w RESEARCH CENTER BORSTEL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; PIRFENIDONE; PREDNISONE;

ANTICOAGULATION; ARTICLE; CONSENSUS DEVELOPMENT; FIBROSING ALVEOLITIS; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-INFLAMMATORY AGENTS; GERMANY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERNATIONALITY; PRACTICE GUIDELINES AS TOPIC; PULMONARY MEDICINE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84873738073     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0032-1326009     Document Type: Article

References (379)

1. American Thoracic Society European Respiratory Society Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. Am J Respir Crit Care Med: 2000; 161 646 664
2. Raghu G., Collard H. R., Egan J. J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med: 2011; 183 788 824
3. Schunemann H. J., Jaeschke R., Cook D. J. et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med: 2006; 174 605 614 (Pubitemid 44330555)
4. American Thoracic Society European Respiratory Society Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med: 2002; 165 277 304
5. Visscher D. W., Myers J. L. Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc: 2006; 3 322 329 (Pubitemid 43845409)
6. Douglas W. W., Ryu J. H., Schroeder D. R. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med: 2000; 161 1172 1178 (Pubitemid 30243826)
7. King T. E. Jr, Tooze J. A., Schwarz M. I. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med: 2001; 164 1171 1181 (Pubitemid 33052246)
8. Gribbin J., Hubbard R. B., Le Jeune I. et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax: 2006; 61 980 985 (Pubitemid 44787169)
9. Scott J., Johnston I., Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ: 1990; 301 1015 1017 (Pubitemid 20381075)
10. Mannino D. M., Etzel R. A., Parrish R. G. Pulmonary fibrosis deaths in the United States, 1979-1991: an analysis of multiple-cause mortality data. Am J Respir Crit Care Med: 1996; 153 1548 1552 (Pubitemid 26141339)
11. Raghu G., Freudenberger T. D., Yang S. et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J: 2006; 27 136 142 (Pubitemid 43092677)
12. Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2006; 174 810 816 (Pubitemid 44511663)
13. Nadrous H. F., Myers J. L., Decker P. A. et al. Idiopathic pulmonary fibrosis in patients younger than 50 years. Mayo Clin Proc: 2005; 80 37 40 (Pubitemid 40075989)
14. Iwai K., Mori T., Yamada N. et al. Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med: 1994; 150 670 675 (Pubitemid 24291493)
15. Coultas D. B., Zumwalt R. E., Black W. C. et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med: 1994; 150 967 972 (Pubitemid 24318021)
16. von Plessen C., Grinde O., Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med: 2003; 97 428 435 (Pubitemid 36410613)
17. Karakatsani A., Papakosta D., Rapti A. et al. Hellenic Interstitial Lung Diseases Group Epidemiology of interstitial lung diseases in Greece. Respir Med: 2009; 103 1122 1129
18. Hubbard R., Lewis S., Richards K. et al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet: 1996; 347 284 289 (Pubitemid 26041039)
19. Baumgartner K. B., Samet J. M., Stidley C. A. et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 1997; 155 242 248 (Pubitemid 27053171)
20. Enomoto T., Usuki J., Azuma A. et al. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest: 2003; 123 2007 2011 (Pubitemid 36706726)
21. Steele M. P., Speer M. C., Loyd J. E. et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med: 2005; 172 1146 1152 (Pubitemid 43066651)
22. Miyake Y., Sasaki S., Yokoyama T. et al. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg: 2005; 49 259 265 (Pubitemid 40547331)
23. Taskar V. S., Coultas D. B. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc: 2006; 3 293 298 (Pubitemid 43845405)
24. Johnston I. D., Prescott R. J., Chalmers J. C. et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax: 1997; 52 38 44 (Pubitemid 27047223)
25. Hubbard R., Cooper M., Antoniak M. et al. Risk of cryptogenic fibrosing alveolitis in metal workers. Lancet: 2000; 355 466 467 (Pubitemid 30085159)
26. Gustafson T., Dahlman-Hoglund A., Nilsson K. et al. Occupational exposure and severe pulmonary fibrosis. Respir Med: 2007; 101 2207 2212 (Pubitemid 47324247)
27. Kitamura H., Ichinose S., Hosoya T. et al. Inhalation of inorganic particles as a risk factor for idiopathic pulmonary fibrosis: elemental microanalysis of pulmonary lymph nodes obtained at autopsy cases. Pathol Res Pract: 2007; 203 575 585 (Pubitemid 47163498)
28. Ueda T., Ohta K., Suzuki N. et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis: 1992; 146 266 268
29. Irving W. L., Day S., Johnston I. D. Idiopathic pulmonary fibrosis and hepatitis C virus infection. Am Rev Respir Dis: 1993; 148 1683 1684 (Pubitemid 24002509)
30. Egan J. J., Stewart J. P., Hasleton P. S. et al. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax: 1995; 50 1234 1239
31. Meliconi R., Andreone P., Fasano L. et al. Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis. Thorax: 1996; 51 315 317 (Pubitemid 26086479)
32. Kuwano K., Nomoto Y., Kunitake R. et al. Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction. Eur Respir J: 1997; 10 1445 1449 (Pubitemid 27311053)
33. Wangoo A., Shaw R. J., Diss T. C. et al. Cryptogenic fibrosing alveolitis: lack of association with Epstein-Barr virus infection. Thorax: 1997; 52 888 891 (Pubitemid 27473931)
34. Yamaguchi S., Kubo K., Fujimoto K. et al. Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha. Thorax: 1997; 52 33 37 (Pubitemid 27047222)
35. Yonemaru M., Kasuga I., Kusumoto H. et al. Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis. Eur Respir J: 1997; 10 2040 2045 (Pubitemid 27406438)
36. Stewart J. P., Egan J. J., Ross A. J. et al. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 1999; 159 1336 1341 (Pubitemid 29202576)
37. Tsukamoto K., Hayakawa H., Sato A. et al. Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax: 2000; 55 958 961
38. Lok S. S., Stewart J. P., Kelly B. G. et al. Epstein-Barr virus and wild p53 in idiopathic pulmonary fibrosis. Respir Med: 2001; 95 787 791 (Pubitemid 33019572)
39. Idilman R., Cetinkaya H., Savas I. et al. Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C. J Med Virol: 2002; 66 34 39 (Pubitemid 34183715)
40. Kelly B. G., Lok S. S., Hasleton P. S. et al. A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2002; 166 510 513
41. Arase Y., Ikeda K., Tsubota A. et al. Usefulness of serum KL-6 for early diagnosis of idiopathic pulmonary fibrosis in patients with hepatitis C virus. Hepatol Res: 2003; 27 89 94 (Pubitemid 37322167)
42. Tang Y. W., Johnson J. E., Browning P. J. et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol: 2003; 41 2633 2640 (Pubitemid 36712478)
43. Procop G. W., Kohn D. J., Johnson J. E. et al. BK and JC polyomaviruses are not associated with idiopathic pulmonary fibrosis. J Clin Microbiol: 2005; 43 1385 1386 (Pubitemid 40364967)
44. Zamo A., Poletti V., Reghellin D. et al. HHV-8 and EBV are not commonly found in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis: 2005; 22 123 128 (Pubitemid 41020017)
45. Tobin R. W., Pope C. E. II, Pellegrini C. A. et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 1998; 158 1804 1808 (Pubitemid 29008818)
46. Patti M. G., Tedesco P., Golden J. et al. Idiopathic pulmonary fibrosis: how often is it really idiopathic? J Gastrointest Surg: 2005; 9 1053 1056
47. el-Serag H. B., Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology: 1997; 113 755 760 (Pubitemid 27381133)
48. D'Ovidio F., Singer L. G., Hadjiliadis D. et al. Prevalence of American Thoracic Society Documents 817 gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg: 2005; 80 1254 1260 (Pubitemid 41354098)
49. Gribbin J., Hubbard R., Smith C. Role of diabetes mellitus and gastrooesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med: 2009; 103 927 931
50. Bitterman P. B., Rennard S. I., Keogh B. A. et al. Familial idiopathic pulmonary fibrosis: evidence of lung inflammation in unaffected family members. N Engl J Med: 1986; 314 1343 1347 (Pubitemid 16122467)
51. Marshall R. P., Puddicombe A., Cookson W. O. et al. Adult familial cryptogenic fibrosing alveolitis in the UK. Thorax: 2000; 55 143 146 (Pubitemid 30245956)
52. Hodgson U., Laitinen T., Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax: 2002; 57 338 342 (Pubitemid 34298932)
53. Allam J. S., Limper A. H. Idiopathic pulmonary fibrosis: is it a familial disease? Curr Opin Pulm Med: 2006; 12 312 317 (Pubitemid 44315774)
54. Lee H., Ryu J. H., Wittmer M. H. et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest: 2005; 127 2034 2041
55. Raghu G., Hert R. Interstitial lung diseases: genetic predisposition and inherited interstitial lung diseases. Sem Respir Med: 1993; 14 323 332 (Pubitemid 23277812)
56. Mageto Y. N., Raghu G. Genetic predisposition of idiopathic pulmonary fibrosis. Curr Opin Pulm Med: 1997; 3 336 340 (Pubitemid 127498378)
57. Yang I. V., Burch L. H., Steele M. P. et al. Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med: 2007; 175 45 54 (Pubitemid 46105308)
58. Hodgson U., Pulkkinen V., Dixon M. et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am J Hum Genet: 2006; 79 149 154 (Pubitemid 43927386)
59. Rosas I. O., Ren P., Avila N. A. et al. Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med: 2007; 176 698 705 (Pubitemid 47503078)
60. Musk A. W., Zilko P. J., Manners P. et al. Genetic studies in familial fibrosing alveolitis. Possible linkage with immunoglobulin allotypes (Gm). Chest: 1986; 89 206 210 (Pubitemid 16156416)
61. Thomas A. Q., Lane K., Phillips J. III et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med: 2002; 165 1322 1328 (Pubitemid 34461748)
62. Selman M., Lin H., Montano M. et al. Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Genet: 2003; 113 542 550 (Pubitemid 37383769)
63. Lawson W. E., Grant S. W., Ambrosini V. et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax: 2004; 59 977 980 (Pubitemid 39490784)
64. Markart P., Ruppert C., Wygrecka M. et al. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. Eur Respir J: 2007; 29 134 137 (Pubitemid 46092009)
65. Wang Y., Kuan P. J., Xing C. et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet: 2009; 84 52 59
66. Armanios M. Y., Chen J. J., Cogan J. D. et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med: 2007; 356 1317 1326 (Pubitemid 46513297)
67. Tsakiri K. D., Cronkhite J. T., Kuan P. J. et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA: 2007; 104 7552 7557 (Pubitemid 47185944)
68. Cronkhite J. T., Xing C., Raghu G. et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med: 2008; 178 729 737
69. Alder J. K., Chen J. J., Lancaster L. et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA: 2008; 105 13051 13056
70. Mushiroda T., Wattanapokayakit S., Takahashi A. et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet: 2008; 45 654 656
71. Renzoni E., Lympany P., Sestini P. et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum: 2000; 43 1633 1640 (Pubitemid 30452485)
72. Whyte M., Hubbard R., Meliconi R. et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med: 2000; 162 755 758 (Pubitemid 30647230)
73. Freeburn R. W., Kendall H., Dobson L. et al. The 39 untranslated region of tumor necrosis factor-alpha is highly conserved in idiopathic pulmonary fibrosis (IPF). Eur Cytokine Netw: 2001; 12 33 38 (Pubitemid 32281186)
74. Pantelidis P., Fanning G. C., Wells A. U. et al. Analysis of tumor necrosis factor-alpha, lymphotoxin-alpha, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2001; 163 1432 1436 (Pubitemid 32506612)
75. Hutyrova B., Pantelidis P., Drabek J. et al. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2002; 165 148 151 (Pubitemid 34084448)
76. Latsi P., Pantelidis P., Vassilakis D. et al. Analysis of IL-12 p40 subunit gene and IFN-gamma G5644A polymorphisms in Idiopathic Pulmonary Fibrosis. Respir Res: 2003; 4 6
77. Whittington H. A., Freeburn R. W., Godinho S. IH et al. Analysis of an IL-10 polymorphism in idiopathic pulmonary fibrosis. Genes Immun: 2003; 4 258 264 (Pubitemid 39562124)
78. Riha R. L., Yang I. A., Rabnott G. C. et al. Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. Intern Med J: 2004; 34 126 129 (Pubitemid 38509996)
79. Vasakova M., Striz I., Slavcev A. et al. Correlation of IL-1alpha and IL-4 gene polymorphisms and clinical parameters in idiopathic pulmonary fibrosis. Scand J Immunol: 2007; 65 265 270 (Pubitemid 46277053)
80. Vasakova M., Striz I., Slavcev A. et al. Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. Tissue Antigens: 2006; 67 229 232 (Pubitemid 43383371)
81. Geddes D. M., Webley M., Brewerton D. A. et al. alpha 1-antitrypsin phenotypes in fibrosing alveolitis and rheumatoid arthritis. Lancet: 1977; 2 1049 1051
82. Hubbard R., Baoku Y., Kalsheker N. et al. Alpha1-antitrypsin phenotypes in patients with cryptogenic fibrosing alveolitis: a case-control study. Eur Respir J: 1997; 10 2881 2883 (Pubitemid 28052805)
83. Morrison C. D., Papp A. C., Hejmanowski A. Q. et al. Increased D allele frequency of the angiotensin-converting enzyme gene in pulmonary fibrosis. Hum Pathol: 2001; 32 521 528 (Pubitemid 32506523)
84. Xaubet A., Marin-Arguedas A., Lario S. et al. Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2003; 168 431 435 (Pubitemid 37046871)
85. Zorzetto M., Ferrarotti I., Campo I. et al. NOD2/CARD15 gene polymorphisms in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis: 2005; 22 180 185 (Pubitemid 41668354)
86. Checa M., Ruiz V., Montano M. et al. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum Genet: 2008; 124 465 472
87. Falfan-Valencia R., Camarena A., Juarez A. et al. Major histocompatibility complex and alveolar epithelial apoptosis in idiopathic pulmonary fibrosis. Hum Genet: 2005; 118 235 244 (Pubitemid 41672085)
88. Lederer D. J., Arcasoy S. M., Barr R. G. et al. Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. Am J Transplant: 2006; 6 2436 2442 (Pubitemid 44359431)
89. Zuo F., Kaminski N., Eugui E. et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA: 2002; 99 6292 6297 (Pubitemid 34493305)
90. Seibold M. A., Wise A. L., Speer M. C. et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med: 2011; 364 1503 1512
91. Zhang Y., Noth I., Garcia J. G. et al. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med: 2011; 364 1576 1577
92. Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mutat Res: 2012; 730 52 58
93. Lawson W. E., Loyd J. E., Degryse A. L. Genetics in pulmonary fibrosis - familial cases provide clues to the pathogenesis of idiopathic pulmonary fibrosis. Am J Med Sci: 2011; 341 439 443
94. Diaz de Leon A., Cronkhite J., Katzenstein A. et al. Telomere Lengths, Pulmonary Fibrosis and Telomerase (TERT) Mutations. PLOS One: 2010; 5 e 10680
95. van Moorsel C., van Oosterhout M., Barlo N. et al. Surfactant Protein C Mutations Are the Basis of a Significant Portion of Adult Familial Pulmonary Fibrosis in a Dutch Cohort. Am J Respir Crit Care Med: 2011; 182 1419 1425
96. Nishimura K., Kitaichi M., Izumi T. et al. Usual interstitial pneumonia: histologic correlation with high-resolution CT. Radiology: 1992; 182 337 342
97. Johkoh T., Muller N. L., Cartier Y. et al. Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology: 1999; 211 555 560 (Pubitemid 29206830)
98. Hansell D. M., Bankier A. A., Macmahon H. et al. Fleischner Society: Glossary of terms for thoracic imaging. Radiology: 2008; 246 697 722
99. Hwang J. H., Misumi S., Sahin H. et al. Computed tomographic features of idiopathic fibrosing interstitial pneumonia: comparison with pulmonary fibrosis related to collagen vascular disease. J Comput Assist Tomogr: 2009; 33 410 415
100. Souza C. A., Muller N. L., Lee K. S. et al. Idiopathic interstitial pneumonias: prevalence of mediastinal lymph node enlargement in 206 patients. AJR Am J Roentgenol: 2006; 186 995 999 (Pubitemid 46100198)
101. Mathieson J. R., Mayo J. R., Staples C. A. et al. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology: 1989; 171 111 116 (Pubitemid 19093054)
102. Hunninghake G. W., Zimmerman M. B., Schwartz D. A. et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2001; 164 193 196 (Pubitemid 34001280)
103. Raghu G., Mageto Y. N., Lockhart D. et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study. Chest: 1999; 116 1168 1174 (Pubitemid 29535965)
104. Grenier P., Valeyre D., Cluzel P. et al. Chronic diffuse interstitial lung disease: diagnostic value of chest radiography and high-resolution CT. Radiology: 1991; 179 123 132
105. Lee K. S., Primack S. L., Staples C. A. et al. Chronic infiltrative lung disease: comparison of diagnostic accuracies of radiography and low- and conventional-dose thin-section CT. Radiology: 1994; 191 669 673 (Pubitemid 24177883)
106. Swensen S. J., Aughenbaugh G. L., Myers J. L. Diffuse lung disease: diagnostic accuracy of CT in patients undergoing surgical biopsy of the lung. Radiology: 1997; 205 229 234 (Pubitemid 27415153)
107. Flaherty K. R., Thwaite E. L., Kazerooni E. A. et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax: 2003; 58 143 148 (Pubitemid 36183002)
108. Quadrelli S., Molinari L., Ciallella L. et al. Radiological versus histopathological diagnosis of usual interstitial pneumonia in the clinical practice: does it have any survival difference? Respiration: 2010; 79 32 37
109. Flaherty K. R., King T. E. Jr, Raghu G. et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med: 2004; 170 904 910 (Pubitemid 39346487)
110. Lynch J. P. III, Saggar R., Weigt S. S. et al. Usual interstitial pneumonia. Semin Respir Crit Care Med: 2006; 27 634 651 (Pubitemid 46048043)
111. Trahan S., Hanak V., Ryu J. H. et al. Role of surgical lung biopsy in separating chronic hypersensitivity pneumonia from usual interstitial pneumonia/idiopathic pulmonary fibrosis: analysis of 31 biopsies from 15 patients. Chest: 2008; 134 126 132 (Pubitemid 352008773)
112. Silva C. I., Muller N. L., Lynch D. A. et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and non-specific interstitial pneumonia by using thin-section CT. Radiology: 2008; 246 288 297 (Pubitemid 350305055)
113. Monaghan H., Wells A. U., Colby T. V. et al. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest: 2004; 125 522 526 (Pubitemid 38223631)
114. Flaherty K. R., Travis W. D., Colby T. V. et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med: 2001; 164 1722 1727 (Pubitemid 33124165)
115. Bensard D. D., McIntyre R. C. Jr, Waring B. J. et al. Comparison of video thoracoscopic lung biopsy to open lung biopsy in the diagnosis of interstitial lung disease. Chest: 1993; 103 765 770 (Pubitemid 23086171)
116. Miller J. D., Urschel J. D., Cox G. et al. A randomized, controlled trial comparing thoracoscopy and limited thoracotomy for lung biopsy in interstitial lung disease. Ann Thorac Surg: 2000; 70 1647 1650
117. Carnochan F. M., Walker W. S., Cameron E. W. Efficacy of video assisted thoracoscopic lung biopsy: an historical comparison with open lung biopsy. Thorax: 1994; 49 361 363 (Pubitemid 24149201)
118. Ferson P. F., Landreneau R. J., Dowling R. D. et al. Comparison of open versus thoracoscopic lung biopsy for diffuse infiltrative pulmonary disease. J Thorac Cardiovasc Surg: 1993; 106 194 199 (Pubitemid 23243235)
119. Vourlekis J. S., Schwarz M. I., Cherniack R. M. et al. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med: 2004; 116 662 668 (Pubitemid 38581111)
120. Ohshimo S., Bonella F., Cui A. et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2009; 179 1043 1047
121. Berbescu E. A., Katzenstein A. A., Snow J. L. et al. Transbronchial biopsy in usual interstitial pneumonia. Chest: 2006; 129 1126 1131
122. Park J. H., Kim D. S., Park I. N. et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med: 2007; 175 705 711
123. Wasicek C. A., Reichlin M., Montes M. et al. Polymyositis and interstitial lung disease in a patient with anti-Jo1 prototype. Am J Med: 1984; 76 538 544 (Pubitemid 14159569)
124. Flaherty K. R., Andrei A., King T. E. Jr et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med: 2007; 175 1054 1060 (Pubitemid 46741757)
125. Carrington C. B., Gaensler E. A., Coutu R. E. et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med: 1978; 298 801 809 (Pubitemid 8313452)
126. Tukiainen P., Taskinen E., Holsti P. et al. Prognosis of cryptogenic fibrosing alveolitis. Thorax: 1983; 38 349 355 (Pubitemid 13086916)
127. Gross T. J., Hunninghake G. W. Idiopathic pulmonary fibrosis. N Engl J Med: 2001; 345 517 525 (Pubitemid 32758505)
128. Ley B., Collard H. R., King T. E. Clinical course and prediction of survival in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med: 2011; 183 431 440
129. Bjoraker J. A., Ryu J. H., Edwin M. K. et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 1998; 157 199 203 (Pubitemid 28071283)
130. Flaherty K. R., Toews G. B., Travis W. D. et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J: 2002; 19 275 283 (Pubitemid 34162828)
131. Nicholson A. G., Colby T. V., du Bois R. M. et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med: 2000; 162 2213 2217 (Pubitemid 32051689)
132. Rudd R. M., Prescott R. J., Chalmers J. C. et al. British Thoracic Society Study on cryptogenic fibrosing alveolitis: Response to treatment and survival. Thorax: 2007; 62 62 66 (Pubitemid 46101768)
133. King T. E. Jr, Schwarz M. I., Brown K. et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med: 2001; 164 1025 1032 (Pubitemid 32971653)
134. Raghu G., Brown K. K., Bradford W. Z. et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med: 2004; 350 125 133 (Pubitemid 38056223)
135. King T. E. Jr, Albera C., Bradford W. Z. et al. INSPIRE Study Group Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet: 2009; 374 222 228
136. King T. E. Jr, Behr J., Brown K. K. et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2008; 177 75 81
137. Raghu G. Idiopathic pulmonary fibrosis: a rational clinical approach. Chest: 1987; 92 148 154 (Pubitemid 17101355)
138. Selman M., Carrillo G., Estrada A. et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS ONE: 2007; 2 e482
139. Mejia M., Carrillo G., Rojas-Serrano J. et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest: 2009; 136 10 15
140. Wells A. U., Desai S. R., Rubens M. B. et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med: 2003; 167 962 969 (Pubitemid 36408161)
141. Lettieri C. J., Nathan S. D., Barnett S. D. et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest: 2006; 129 746 752
142. Collard H. R., Moore B. B., Flaherty K. R. et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2007; 176 636 643
143. Azuma A., Nukiwa T., Tsuboi E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2005; 171 1040 1047 (Pubitemid 40616955)
144. Song J. W., Hong S-B, Koh Y. et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J: 2011; 37 356 363
145. Martinez F. J., Safrin S., Weycker D. et al. IPF Study Group The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med: 2005; 142 963 967
146. Panos R. J., Mortenson R. L., Niccoli S. A. et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med: 1990; 88 396 404 (Pubitemid 20147276)
147. Akira M., Hamada H., Sakatani M. et al. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol: 1997; 168 79 83 (Pubitemid 27014751)
148. Ambrosini V., Cancellieri A., Chilosi M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J: 2003; 22 821 826 (Pubitemid 37369573)
149. Kim D. S., Park J. H., Park B. K. et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J: 2006; 27 143 150 (Pubitemid 43092678)
150. Kondoh Y., Taniguchi H., Kawabata Y. et al. Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathologic findings in three cases. Chest: 1993; 103 1808 1812 (Pubitemid 23174318)
151. Kondoh Y., Taniguchi H., Yokoi T. et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J: 2005; 25 528 533 (Pubitemid 40331185)
152. Kubo H., Nakayama K., Yanai M. et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest: 2005; 128 1475 1482 (Pubitemid 41324435)
153. Parambil J. G., Myers J. L., Ryu J. H. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest: 2005; 128 3310 3315 (Pubitemid 41698656)
154. Tiitto L., Bloigu R., Heiskanen U. et al. Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia. Thorax: 2006; 61 1091 1095 (Pubitemid 44852029)
155. Rice A. J., Wells A. U., Bouros D. et al. Terminal diffuse alveolar damage in relation to interstitial pneumonias: an autopsy study. Am J Clin Pathol: 2003; 119 709 714 (Pubitemid 37046392)
156. Churg A., Muller N. L., Silva C. IS et al. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol: 2007; 31 277 284 (Pubitemid 46175029)
157. Kondo A., Saiki S. Acute exacerbation in idiopathic interstitial pneumonia (IIP). In: Harasawa M., Fukuchi Y., Morinari H. eds. Interstitial pneumonia of unknown etiology. Tokyo University of Tokyo Press: 1989; 33 42
158. Konishi K., Gibson K. F., Lindell K. O. et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2009; 180 167 175
159. Wootton S. C., Kim D. S., Kondoh Y. et al. Viral infection in acute exacerbation of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med: 2011; 183 1698 1702
160. Sakamoto K., Taniguchi H., Kondoh Y. et al. Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease. Eur Respir Rev: 2009; 18 129 132
161. Kondoh Y., Taniguchi H., Kataoka K. et al. Prognostic factors in rapidly progressive interstitial pneumonia. Respirology: 2010; 15 257 264
162. Kumar P., Goldstraw P., Yamada K. et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg: 2003; 125 1321 1327 (Pubitemid 36759232)
163. Yuksel M., Ozyurtkan M. O., Bostanci K. et al. Acute exacerbation of interstitial fibrosis after pulmonary resection. Ann Thorac Surg: 2006; 82 336 338 (Pubitemid 43949242)
164. Utz J. P., Ryu J. H., Douglas W. W. et al. High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J: 2001; 17 175 179 (Pubitemid 32600574)
165. Zegdi R., Azorin J., Tremblay B. et al. Videothoracoscopic lung biopsy in diffuse infiltrative lung diseases: a 5-year surgical experience. Ann Thorac Surg: 1998; 66 1170 1173 (Pubitemid 28518045)
166. Kondoh Y., Taniguchi H., Kitaichi M. et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med: 2006; 100 1753 1759 (Pubitemid 44283759)
167. Hiwatari N., Shimura S., Takishima T. et al. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J Exp Med: 1994; 174 379 386
168. Olson A. L., Swigris J. J., Lezotte D. C. et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med: 2007; 176 277 284 (Pubitemid 47195878)
169. Navaratnam V., Fleming K. M., West J. et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax: 2011; 66 462 467
170. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2007. CA Cancer J Clin: 2007; 57 43 66 (Pubitemid 46148091)
171. Olson A. L., Swigris J. J., Raghu G. et al. Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. Chest: 2009; 136 16 22
172. Fernandez Perez E. R., Daniels C. E., Schroeder D. R. et al. Incidence, prevalence and clinical course of Idiopathic Pulmonary Fibrosis: a population-based study. Chest: 2010; 137 129 37
173. Hubbard R. B., Smith C., Le Jeune I. et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med: 2008; 178 1257 1261
174. Nadrous H. F., Pellikka P. A., Krowka M. J. et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest: 2005; 128 2393 2399 (Pubitemid 41507585)
175. Collard H. R., Ryu J. H., Douglas W. W. et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest: 2004; 125 2169 2174 (Pubitemid 38788186)
176. Hubbard R., Venn A., Smith C. et al. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Am J Respir Crit Care Med: 1998; 157 743 747
177. Schwartz D. A., Van Fossen D. S., Davis C. S. et al. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 1994; 149 444 449 (Pubitemid 24068993)
178. Enomoto N., Suda T., Kato M. et al. Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest: 2006; 130 22 29 (Pubitemid 44121414)
179. Nadrous H. F., Pellikka P. A., Krowka M. J. et al. The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest: 2005; 128 616 617
180. Jegal Y., Kim D. S., Shim T. S. et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med: 2005; 171 639 644 (Pubitemid 40365421)
181. Wells A. U., Hogaboam C. M. Update in diffuse parenchymal lung disease 2007. Am J Respir Crit Care Med: 2008; 177 580 584 (Pubitemid 351442164)
182. du Bois R. M., Weycker D., Albera C. et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2011; 184 459 466
183. Turner-Warwick M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax: 1980; 35 593 599 (Pubitemid 10055764)
184. Schwartz D. A., Helmers R. A., Galvin J. R. et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 1994; 149 450 454 (Pubitemid 24068994)
185. Nishiyama O., Taniguchi H., Kondoh Y. et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis: what is the main contributing factor? Respir Med: 2005; 99 408 414 (Pubitemid 40347823)
186. Nishiyama O., Taniguchi H., Kondoh Y. et al. A simple assessment of dyspnea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J: 2010; 36 1067 1072
187. Watters L. C., King T. E. Jr, Schwarz M. I. et al. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis: 1986; 133 97 103 (Pubitemid 16189105)
188. Witek T. J. Jr, Mahler D. A. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J: 2003; 21 267 272 (Pubitemid 36204541)
189. Kupferberg D. H., Kaplan R. M., Slymen D. J. et al. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil: 2005; 25 370 377 (Pubitemid 44510067)
190. Collard H. R., King T. E. Jr, Bartelson B. B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2003; 168 538 542 (Pubitemid 37088595)
191. King T. E. Jr, Safrin S., Starko K. M. et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest: 2005; 127 171 177 (Pubitemid 41724573)
192. Hallstrand T. S., Boitano L. J., Johnson W. C. et al. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J: 2005; 25 96 103 (Pubitemid 40207737)
193. Hamada K., Nagai S., Tanaka S. et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest: 2007; 131 650 656 (Pubitemid 46446853)
194. Egan J. J., Martinez F. J., Wells A. U. et al. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax: 2005; 60 270 273 (Pubitemid 40522359)
195. Latsi P. I., du Bois R. M., Nicholson A. G. et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med: 2003; 168 531 537 (Pubitemid 37088594)
196. Fell C. D., Liu L. X., Motika C. et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2009; 179 402 407
197. Flaherty K. R., Mumford J. A., Murray S. et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med: 2003; 168 543 548 (Pubitemid 37088596)
198. du Bois R. M., Weycker D., Albera C. et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med: 2011; 184 1382 1389
199. Lynch D. A., Godwin J. D., Safrin S. et al. Idiopathic Pulmonary Fibrosis Study Group High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med: 2005; 172 488 493 (Pubitemid 41117395)
200. Best A. C., Meng J., Lynch A. M. et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology: 2008; 246 935 940
201. Jeong Y. J., Lee K. S., Muller N. L. et al. Usual interstitial pneumonia and non-specific interstitial pneumonia: serial thin-section CT findings correlated with pulmonary function. Korean J Radiol: 2005; 6 143 152 (Pubitemid 41296873)
202. Shin K. M., Lee K. S., Chung M. P. et al. Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study. Radiology: 2008; 249 328 337
203. Sumikawa H., Johkoh T., Colby T. V. et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med: 2008; 177 433 439 (Pubitemid 351317587)
204. Lama V. N., Flaherty K. R., Toews G. B. et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med: 2003; 168 1084 1090 (Pubitemid 37338937)
205. Enright P. L. The six-minute walk test. Respir Care: 2003; 48 783 785 (Pubitemid 47377828)
206. Lederer D. J., Arcasoy S. M., Wilt J. S. et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2006; 174 659 664 (Pubitemid 44395333)
207. Swigris J. J., Swick J., Wamboldt F. S. et al. Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest: 2009; 136 841 848
208. Caminati A., Bianchi A., Cassandro R. et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med: 2009; 103 117 123
209. Eaton T., Young P., Milne D. et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med: 2005; 171 1150 1157 (Pubitemid 40663728)
210. du Bois R. M., Weycker D., Albera C. et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med: 2011; 183 1231 1237
211. Nicholson A. G., Fulford L. G., Colby T. V. et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2002; 166 173 177 (Pubitemid 34765453)
212. Flaherty K. R., Colby T. V., Toews G. B. et al. Differential presence of fibroblastic foci in UIP patients with or without conntective tissue disease. Am J Respir Crit Care Med: 2001; 163 A983
213. Hanak V., Ryu J. H., de Carvalho E. et al. Profusion of fibroblast foci in patients with idiopathic pulmonary fibrosis does not predict outcome. Respir Med: 2008; 102 852 856
214. Arcasoy S. M., Christie J. D., Ferrari V. A. et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med: 2003; 167 735 740 (Pubitemid 36801751)
215. Nathan S. D., Shlobin O. A., Barnett S. D. et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med: 2008; 102 1305 1310
216. Fisher M. R., Forfia P. R., Chamera E. et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med: 2009; 179 615 621
217. Modrykamien A. M., Gudavalli R., McCarthy K. et al. Echocardiography, 6-minute walk distance, and distance saturation product as predictors of pulmonary arterial hypertension in Idiopathic Pulmonary Fibrosis. Respir Care: 2010; 55 584 88
218. Corte T. J., Wort S. J., Gatzoulis M. A. et al. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax: 2009; 64 883 888
219. Hoeper M. M., Andreas S., Bastian A. et al. Pulmonary hypertension due to chronic lung disease: updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol: 2011; 152S 45 53
220. Cottin V., Nunes H., Brillet P. Y. et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J: 2005; 26 586 593 (Pubitemid 41448654)
221. Nathan S. D., Basavaraj A., Reichner C. et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med: 2010; 104 1035 1040
222. Lee J. S., Collard H. R., Raghu G. et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis. Am J Med: 2010; 123 304 311
223. Bouros D., Hatzakis K., Labrakis H. et al. Association of malignancy with diseases causing interstitial pulmonary changes. Chest: 2002; 212 1278 1289 (Pubitemid 34280454)
224. Mermigkis C., Stagaki E., Amfilochiou A. et al. Sleep quality and associated daytime consequences in patients with idiopathic pulmonary fibrosis. Med Princ Pract: 2009; 18 10 15
225. Stahel R. A., Gilks W. R., Lehmann H. P. et al. Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int J Cancer Suppl: 1994; 8 6 26 (Pubitemid 24188951)
226. Kohno N., Kyoizumi S., Awaya Y. et al. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest: 1989; 96 68 73 (Pubitemid 19176416)
227. Yokoyama A., Kondo K., Nakajima M. et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology: 2006; 11 164 168 (Pubitemid 43356896)
228. Greene K. E., King T. E. Jr, Kuroki Y. et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J: 2002; 19 439 446 (Pubitemid 34256957)
229. Kinder B. W., Brown K. K., McCormack F. X. et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest: 2009; 135 1557 1563
230. Takahashi H., Fujishima T., Koba H. et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and American Thoracic Society Documents 821 their relationship to disease extent. Am J Respir Crit Care Med: 2000; 162 1109 1114
231. Prasse A., Probst C., Bargagli E. et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2009; 179 717 723
232. Leuchte H. H., Baumgartner R. A., Nounou M. E. et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med: 2006; 173 744 750
233. Leuchte H. H., Neurohr C., Baumgartner R. et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med: 2004; 170 360 365 (Pubitemid 39214607)
234. Song J. W., Song J. K., Kim D. S. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med: 2009; 103 180 186
235. Shinoda H., Tasaka S., Fujishima S. et al. Elevated CC chemokine level in bronchoalveolar lavage fluid is predictive of a poor outcome of idiopathic pulmonary fibrosis. Respiration: 2009; 78 285 292
236. Rosas I. O., Richards T. J., Konishi K. et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med: 2008; 5 e93
237. Phelps D. S., Umstead T. M., Mejia M. et al. Increased surfactant protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest: 2004; 125 617 625 (Pubitemid 38223644)
238. McCormack F. X., King T. E. Jr, Bucher B. L. et al. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 1995; 152 751 759
239. Kinder B. W., Brown K. K., Schwarz M. I. et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest: 2008; 133 226 232
240. Moeller A., Gilpin S. E., Ask K. et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2009; 179 588 594
241. Richards T. J., Kaminski N., Baribaud F. et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2012; 185 67 76
242. Davies H. R., Richeldi L., Walters E. H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev: 2003; 03 CD003134
243. Richeldi L., Davies H. R., Ferrara G. et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev: 2003; 3 CD002880
244. Turner-Warwick M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax: 1980; 35 593 599 (Pubitemid 10055764)
245. Gay S. E., Kazerooni E. A., Toews G. B. et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med: 1998; 157 1063 1072
246. Flaherty K. R., Toews G. B., Lynch J. P. III et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med: 2001; 110 278 282 (Pubitemid 32187288)
247. Nagai S., Kitaichi M., Hamada K. et al. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarcoidosis Vasc Diffuse Lung Dis: 1999; 16 209 214 (Pubitemid 29469102)
248. Entzian P., Schlaak M., Seitzer U. et al. Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung: 1997; 175 41 51 (Pubitemid 26412519)
249. Peters S. G., McDougall J. C., Douglas W. W. et al. Colchicine in the treatment of pulmonary fibrosis. Chest: 1993; 103 101 104 (Pubitemid 23027240)
250. Selman M., Carrillo G., Salas J. et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest: 1998; 114 507 512 (Pubitemid 28387531)
251. Fiorucci E., Lucantoni G., Paone G. et al. Colchicine, cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens. Eur Rev Med Pharmacol Sci: 2008; 12 105 111 (Pubitemid 351833266)
252. Antoniou K. M., Nicholson A. G., Dimadi M. et al. Longterm clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J: 2006; 28 496 504 (Pubitemid 44794663)
253. Douglas W. W., Ryu J. H., Swensen S. J. et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis: a randomized prospective study. Am J Respir Crit Care Med: 1998; 158 220 225 (Pubitemid 28337184)
254. Alton E. W., Johnson M., Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir Med: 1989; 83 277 279
255. Moolman J. A., Bardin P. G., Rossouw D. J. et al. Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax: 1991; 46 592 595
256. Homma S., Sakamoto S., Kawabata M. et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med: 2005; 44 1144 1150
257. Grgic A., Lausberg H., Heinrich M. et al. Progression of fibrosis in usual interstitial pneumonia: serial evaluation of the native lung after single lung transplantation. Respiration: 2008; 76 139 145
258. Wahidi M. M., Ravenel J., Palmer S. M. et al. Progression of idiopathic pulmonary fibrosis in native lungs after single lung transplantation. Chest: 2002; 121 2072 2076 (Pubitemid 34634439)
259. Winterbauer R. H., Hammar S. P., Hallman K. O. et al. Diffuse interstitial pneumonitis: clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med: 1978; 65 661 672 (Pubitemid 9039525)
260. Raghu G., Depaso W. J., Cain K. et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis: 1991; 144 291 296
261. Johnson M. A., Kwan S., Snell N. J. et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax: 1989; 44 80 288
262. Collard H. R., Ryu J. H., Douglas W. W. et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest: 2004; 125 2169 2174 (Pubitemid 38788186)
263. Pereira C. AC, Malheiros T., Coletta E. M. et al. Survival in idiopathic pulmonary fibrosiscytotoxic agents compared to corticosteroids. Respir Med: 2006; 100 340 347 (Pubitemid 43078988)
264. Cantin A. M., Hubbard R. C., Crystal R. G. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis: 1989; 139 370 372 (Pubitemid 19057410)
265. Behr J., Maier K., Degenkolb B. et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med: 1997; 156 1897 1901 (Pubitemid 28011799)
266. Demedts M., Behr J., Buhl R. et al. IFIGENIA Study Group High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med: 2005; 353 2229 2242 (Pubitemid 41697286)
267. Hunninghake G. W. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med: 2005; 353 2285 2287 (Pubitemid 41699756)
268. Wells A. U. Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled. Eur Respir J: 2006; 27 664 666 (Pubitemid 44914184)
269. Ziesche R., Hofbauer E., Wittmann K. et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med: 1999; 341 1264 1269 (Pubitemid 29489741)
270. Raghu G., Brown K. K., Bradford W. Z. et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med: 2004; 350 125 133 (Pubitemid 38056223)
271. King T. E. Jr, Albera C., Bradford W. Z. INSPIRE Study Group et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet: 2009; 374 222 228
272. Thannickal V. J., Flaherty K. R., Martinez F. J. et al. Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin Pharmacother: 2004; 5 1671 1686 (Pubitemid 39117710)
273. King T. E. Jr, Behr J., Brown K. K. et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2008; 177 75 81
274. Raghu G., King T. E. Jr, Behr J. et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J: 2010; 35 118 123
275. Mohler K. M., Torrance D. S., Smith C. A. et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol: 1993; 151 1548 1561 (Pubitemid 23219293)
276. Sime P. J., Marr R. A., Gauldie D. et al. Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am J Pathol: 1998; 153 825 832 (Pubitemid 28419035)
277. Piguet P. F., Ribaux C., Karpuz V. et al. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol: 1993; 143 651 655 (Pubitemid 24058221)
278. Raghu G., Brown K. K., Costabel U. et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med: 2008; 178 948 955
279. Kubo H., Nakayama K., Yanai M. et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest: 2005; 128 1475 1482 (Pubitemid 41324435)
280. Raghu G., Johnson W. C., Lockhart D. et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med: 1999; 159 1061 1069 (Pubitemid 29202536)
281. Nagai S., Hamada K., Shigematsu M. et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med: 2002; 41 1118 1123 (Pubitemid 36150010)
282. Azuma A., Nukiwa T., Tsuboi E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2005; 171 1040 1047 (Pubitemid 40616955)
283. Taniguchi H., Ebina M., Kondoh Y. et al. Pirfenidone Clinical Study Group in Japan Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J: 2010; 35 821 829
284. Seymour S. Briefing Information for the March 9, 2010 Meeting of the Pulmonary-Allergy Drugs Advisory Committee. NDA 22-535. Washington, D.C. US Food and Drug Administration: 2010; Available from: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary- AllergyDrugsAdvisoryCommittee/UCM203081.pdf [accessed 2010 May 10]
285. Seymour S. Division Summary: Overview of the FDA background materials for New Drug Application (NDA) 22-535, Esbriet (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce the decline in lung function. In: Seymour S. ed. FDA Briefing Information for the March 9, 2010 Meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC). NDA 22-535. Washington, D.C. US Food and Drug Administration: 2010; 2 20 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM203081.pdf [accessed 2010 May 10]
286. Karimi-Shah B. Esbriet (pirfenidone) 2403 mg/day to reduce the decline in lung function in patients with idiopathic pulmonary fibrosis (Clinical Briefing Document). In: Seymour S. ed. FDA Briefing Information for the March 9, 2010 Meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC). NDA 22-535. Washington, D.C. US Food and Drug Administration Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM203081.pdf [accessed 2010 May 10]
287. Zhou F. Pirfenidone capsules [three 267-mg capsules TID] for treatment of patients with idiopathic pulmonary fibrosis to reduce decline in lung function (Statistical Briefing Document). In: Seymour S. ed. FDA Briefing Information for the March 9, 2010 Meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC). NDA 22-535. Washington, D.C. US Food and Drug Administration: 2010; 110 158 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/ UCM203081.pdf [accessed 2010 May 10]
288. King T. E. Jr, Brown K. K., Raghu G. et al. BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med: 2011; 184 92 99
289. Behr J., Costabel U., Worth H. Stellungnahme der DGP zur Pressemitteilung des National Heart Lung and Blood Institute zur PANTHER-Studie bei IPF-Patienten vom 21.10.2011. Pneumologie: 2011; 67 724 725
290. Noble P. W., Albera C., Bradford W. Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet: 2011; 377 1760 1769
291. Sagnolo P., Del Giovane C., Luppi F. et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Datbase Syst Rev: 2010; 9 CD003134
292. Daniels C. E., Lasky J. A., Limper A. H. et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med: 2010; 181 604 610
293. Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. New Engl J Med: 2011; 365 1079 1087
294. Morrison D. A., Stovall J. R. Increased exercise capacity in hypoxemic patients after long-term oxygen therapy. Chest: 1992; 102 542 550
295. Nocturnal Oxygen Therapy Trial Group Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med: 1980; 93 391 398
296. Longterm domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party. Lancet: 1981; 1 681 686
297. Mason D. P., Brizzio M. E., Alster J. M. et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg: 2007; 84 1121 1128 (Pubitemid 47417865)
298. Keating D., Levvey B., Kotsimbos T. et al. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc: 2009; 41 289 291
299. Christie J. D., Edwards L. B., Kucheryavaya A. Y. et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report - 2011. J Heart Lung Transplant: 2011; 30 1104 1122
300. Thabut G., Mal H., Castier Y. et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg: 2003; 126 469 475 (Pubitemid 37048514)
301. Orens J., Estenne M., Arcasoy S. et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant: 2006; 25 745 55 (Pubitemid 43963375)
302. Thabut G., Christie J. D., Ravaud P. et al. Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann Intern Med: 2009; 151 767 774
303. Kim D. S., Park J. H., Park B. K. et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J: 2006; 27 143 150 (Pubitemid 43092678)
304. Blivet S., Philit F., Sab J. M. et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. Chest: 2001; 120 209 212 (Pubitemid 32744881)
305. Molina-Molina M., Badia J. R., Marin-Arguedas A. et al. Outcomes and clinical characteristics of patients with pulmonary fibrosis and respiratory failure admitted to an intensive care unit: a study of 20 cases. Med Clin (Barc): 2003; 121 63 67 (Pubitemid 36889512)
306. Saydain G., Islam A., Afessa B. et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med: 2002; 166 839 842
307. Nava S., Rubini F. Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. Thorax: 1999; 54 390 395 (Pubitemid 29199775)
308. Stern J. B., Mal H., Groussard O. et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest: 2001; 120 213 219 (Pubitemid 32744882)
309. Al-Hameed F. M., Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J: 2004; 11 117 122 (Pubitemid 38519170)
310. Fumeaux T., Rothmeier C., Jolliet P. Outcome of mechanical ventilation for acute respiratory failure in patients with pulmonary fibrosis. Intensive Care Med: 2001; 27 1868 1874 (Pubitemid 33145071)
311. Pitsiou G., Ioannis Trigonis I., Tsiata E. et al. Outcome of patients with pulmonary fibrosis admitted to the ICU for acute respiratory failure. Eur Respir J Suppl: 2006; 28 E650
312. Mollica C., Paone G., Conti V. et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration: 2010; 79 209 215
313. Rangappa P., Moran J. L. Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis. Crit Care Resusc: 2009; 11 102 109
314. Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med: 2008; 102 1355 1359
315. Mason D. P., Thuita L., Nowicki E. R. et al. Should lung transplantation be performed for patients on mechanical respiratory support? The US experience. J Thorac Cardiovasc Surg: 2010; 139 765 773
316. Holland A. E., Hill C. J., Conron M. et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax: 2008; 63 549 554 (Pubitemid 351831168)
317. Nishiyama O., Kondoh Y., Kimura T. et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology: 2008; 13 394 399 (Pubitemid 351503129)
318. Ferreira A., Garvey C., Connors G. L. et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest: 2009; 135 442 447
319. Ferreira G., Feuerman M., Spiegler P. Results of an 8-week, outpatient pulmonary rehabilitation program on patients with and without chronic obstructive pulmonary disease. J Cardiopulm Rehabil: 2006; 26 54 60 (Pubitemid 44474317)
320. Jastrzebski D., Gumola A., Gawlik R. et al. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J Physiol Pharmacol: 2006; 57 139 148 (Pubitemid 44638195)
321. Naji N. A., Connor M. C., Donnelly S. C. et al. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehabil: 2006; 26 237 243 (Pubitemid 44616970)
322. Magnussen H., Kirsten A. M., Köhler D. et al. Deutsche Gesellschaft Für Pneumologie und Beatmungsmedizin e.V Guidelines for long-term-oxygen therapy. German Society for Pneumology and Respiratory Medicine. Pneumologie: 2008; 62 748 756
323. Fischer S., Hoeper M. M., Bein T. et al. Interventional lung assist: a new concept of protective ventilation in bridge to lung transplantation. ASAIO J: 2008; 54 3 10
324. Lancaster L. H., Mason W. R., Parnell J. A. et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest: 2009; 136 772 778
325. Collard H. R., Moore B. B., Flaherty K. R. et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2007; 176 636 643
326. Akira M., Hamada H., Sakatani M. et al. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol: 1997; 168 79 83 (Pubitemid 27014751)
327. Ambrosini V., Cancellieri A., Chilosi M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J: 2003; 22 821 826 (Pubitemid 37369573)
328. Parambil J. G., Myers J. L., Ryu J. H. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest: 2005; 128 3310 3315 (Pubitemid 41698656)
329. Rice A. J., Wells A. U., Bouros D. et al. Terminal diffuse alveolar damage in relation to interstitial pneumonias: an autopsy study. Am J Clin Pathol: 2003; 119 709 714 (Pubitemid 37046392)
330. Kondo A., Saiki S. Acute exacerbation in idiopathic interstitial pneumonia (IIP). In: Harasawa M., Fukuchi Y., Morinari H. ed. Interstitial pneumonia of unknown etiology. Tokyo University of Tokyo Press: 1989; 33 42
331. Kim D. S., Collard H. R., King T. E. Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc: 2006; 3 285 292 (Pubitemid 43845404)
332. Sakamoto S., Homma S., Miyamoto A. et al. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med: 2010; 49 109 115
333. Olschewski H., Ghofrani H. A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med: 1999; 160 600 607 (Pubitemid 29380679)
334. Minai O. A., Sahoo D., Chapman J. T. et al. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir Med: 2008; 102 1015 1020
335. Ghofrani H. A., Wiedemann R., Rose F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet: 2002; 360 895 900 (Pubitemid 35283832)
336. Madden B. P., Allenby M., Loke T. et al. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol: 2006; 44 372 376
337. Collard H. R., Anstrom K. J., Schwarz M. I. et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest: 2007; 131 897 899 (Pubitemid 46446887)
338. Raghu G., Freudenberger T. D., Yang S. et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J: 2006; 27 136 142 (Pubitemid 43092677)
339. Tobin R. W., Pope C. E. II, Pellegrini C. A. et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 1998; 158 1804 1808 (Pubitemid 29008818)
340. Sweet M. P., Patti M. G., Leard L. E. et al. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg: 2007; 133 1078 1084 (Pubitemid 46435907)
341. Marik P. E. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med: 2001; 344 665 671 (Pubitemid 32183583)
342. Barnes T. W., Vassallo R., Tazelaar H. D. et al. Diffuse bronchiolar disease due to chronic occult aspiration. Mayo Clin Proc: 2006; 81 172 176 (Pubitemid 43205769)
343. Davis R. D. Jr, Lau C. L., Eubanks S. et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg: 2003; 125 533 542 (Pubitemid 36373899)
344. Linden P. A., Gilbert R. J., Yeap B. Y. et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg: 2006; 131 438 446 (Pubitemid 43121569)
345. Hope-Gill B. DM, Hilldrup S., Davies C. et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2003; 168 995 1002 (Pubitemid 37267179)
346. Horton M. R., Danoff S. K., Lechtzin N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax: 2008; 63 749
347. Allen S., Raut S., Woollard J. et al. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat Med: 2005; 19 128 130 (Pubitemid 40443695)
348. Jegal Y., Kim D. S., Shim T. S. et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med: 2005; 171 639 644 (Pubitemid 40365421)
349. Collard H. R., King T. E. Jr, Bartelson B. B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2003; 168 538 542 (Pubitemid 37088595)
350. King T. E. Jr, Safrin S., Starko K. M. et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest: 2005; 127 171 177 (Pubitemid 41724573)
351. Latsi P. I., du Bois R. M., Nicholson A. G. et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med: 2003; 168 531 537 (Pubitemid 37088594)
352. Flaherty K. R., Mumford J. A., Murray S. et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med: 2003; 168 543 548 (Pubitemid 37088596)
353. Zappala C. J., Latsi P. I., Nicholson A. G. et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J: 2010; 35 830 836
354. Miller M. R., Crapo R., Hankinson J. et al. ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J: 2005; 26 153 161 (Pubitemid 40945944)
355. Miller M. R., Hankinson J., Brusasco V. et al. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J: 2005; 26 319 338 (Pubitemid 41079078)
356. Wanger J., Clausen J. L., Coates A. et al. Standardisation of the measurement of lung volumes. Eur Respir J: 2005; 26 511 522 (Pubitemid 41264217)
357. Macintyre N., Crapo R. O., Viegi G. et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J: 2005; 26 720 735 (Pubitemid 41448672)
358. Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. Eur Respir J: 2005; 26 948 968 (Pubitemid 41632054)
359. Selman M., King T. E. Jr, Pardo A. American Thoracic Society European Respiratory Society American College of Chest Physicians Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med: 2001; 134 136 151 (Pubitemid 32096342)
360. Akagi T., Matsumoto T., Harada T. et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med: 2009; 103 1209 1215
361. Mura M., Zompatori M., Pacilli A. MG et al. The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis. Respir Care: 2006; 51 257 265 (Pubitemid 46888402)
362. Cottin V., Cordier J. F. Combined pulmonary fibrosis and emphysema: an experimental and clinically relevant phenotype. Am J Respir Crit Care Med: 2005; 172 1605 1606
363. Wiggins J., Strickland B., Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med: 1990; 84 365 369 (Pubitemid 20287410)
364. Martinez F. J., Safrin S., Weycker D. IPF Study Group et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med: 2005; 142 963 967
365. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med: 2002; 166 111 117
366. Arcasoy S. M., Christie J. D., Ferrari V. A. et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med: 2003; 167 735 740 (Pubitemid 36801751)
367. Fisher M. R., Forfia P. R., Chamera E. et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med: 2009; 179 615 621
368. Nathan S. D., Noble P. W., Tuder R. M. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med: 2007; 175 875 880 (Pubitemid 46684695)
369. Leuchte H. H., Baumgartner R. A., Nounou M. E. et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med: 2006; 173 744 750
370. Leuchte H. H., Neurohr C., Baumgartner R. et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med: 2004; 170 360 365 (Pubitemid 39214607)
371. Zisman D. A., Karlamangla A. S., Kawut S. M. et al. Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest: 2008; 133 640 645 (Pubitemid 351367371)
372. Egan J. J., Adamali H. et al. Ganciclovir Antiviral Therapy in Advanced Idiopathic Pulmonary Fibrosis: An Open Pilot Study. Pulmonary Medicine: 2011; doi 10.1155/2011/24080, Epub 2011 Apr 7
373. Zisman D. A., Schwarz M., Anstrom K. J. Idiopathic Pulmonary Fibrosis Clinical Research Network et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med: 2010; 363 620 628
374. Hoeper M. M., Halank M., Wilkens H. et al. Riociguat for patients with pulmonary hypertension associated with interstitial lung disease. http://www.phaonlineuniv.org/node/5134
375. The Idiopathic Pulmonary Fibrosis Clinical Research Network Prednisone, Azathiorpine, and n-Acetylcysteine for pulmonary fibrosis. N Engl J Med: 2012; 366 1968 1977
376. Behr J. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med: 2012; 367 869 (letter), author reply 870 - 871
377. Wells A. U., Behr J., Costabel U. et al. Triple therapy in idiopathic pulmonary fibrosis: an alarming press release. Eur Respir J: 2012; 39 805 806
378. Noth I., Anstrom S. B., de Andrade J. et al. A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med: 2012; 186 88 95
379. Müller-Quernheim J., Wells A. Evidence-based recommendations in idiopathic pulmonary fibrosis: a year is a long time in interstitial lung disease. Am J Respir Crit Care Med: 2012; 186 5 7